# AbbVie Stock Q3 2026: Revenue +10% on Skyrizi and Rinvoq
> AbbVie stock Q3 2026: revenue up 10% to $17.4bn as Skyrizi and Rinvoq grew 23-24%, EPS guidance raised, dividend up 5.2%. Our ABBV value and risks.

Agent brief for this QSI Labs research article. Prefer this file for quick facts; use the HTML page for the full human layout, or article.md for the full text.

## Facts
- Ticker: ABBV
- QSILabs fair value: $168.02 USD
- Price: $294.89 (as of 2026-10-30)
- As of: Q3 2026 results (quarter ended 2026-09-30); price as of 2026-10-30 close
- Published: 2026-11-02
- Updated: 2026-11-02
- Author: QSI Labs Research
- Canonical: https://www.quantitativesuperintelligencelabs.com/research/abbvie-stock-q3-2026-earnings-skyrizi-rinvoq/

## Short answer
AbbVie stock in Q3 2026 rests on two immunology drugs. Skyrizi and Rinvoq brought in $8.48bn of AbbVie's $17.40bn of quarterly revenue, up 23% between them, and supplied $1.59bn of the $1.63bn increase in total revenue. AbbVie raised its 2026 adjusted EPS guidance to $13.95-13.99 and its dividend by 5.2%. Our risk-adjusted NPV puts AbbVie at $168.02 per share, about 43% below the $294.89 close on 30 October 2026: the market is paying for growth well beyond Skyrizi's and Rinvoq's patents, and our model does not.

## Key takeaways
- Valuation: QSILabs values AbbVie Inc. (NYSE: ABBV) at $168.02 per share as of Q3 2026, against a $294.89 close on 30 October 2026, about 43% below the market price. Our bear and bull cases are $130.22 and $210.21. Before these results our model gave $160.05.
- Q3 2026 results: AbbVie's revenue rose 10.3% to $17.40bn in the quarter ended 30 September 2026; net earnings were $4.22bn, diluted EPS was $2.37 and adjusted EPS was $3.82, against $1.86 a year earlier.
- Skyrizi and Rinvoq: Skyrizi ($5.78bn, +22.7%) and Rinvoq ($2.71bn, +23.9%) made up 49% of Q3 revenue, against 44% a year earlier.
- Guidance and dividend: AbbVie now expects 2026 adjusted EPS of $13.95-13.99 (previously $13.76-13.96) and will pay a quarterly dividend of $1.82 a share from February 2027, up from $1.73.
- Quality of the beat: stripping out acquired IPR&D, adjusted EPS rose about 17%, from $3.36 to $3.93. The headline doubling mostly reflects a lighter quarter for deal charges.
- Pipeline: AbbVie filed etentamig for multiple myeloma, reported a positive Phase 3 for lutikizumab in hidradenitis suppurativa, won approval for Juvmo in Parkinson's disease and closed the Apogee Therapeutics acquisition for about $10.9bn.

## Full versions
- [HTML](https://www.quantitativesuperintelligencelabs.com/research/abbvie-stock-q3-2026-earnings-skyrizi-rinvoq/)
- [Markdown](https://www.quantitativesuperintelligencelabs.com/research/abbvie-stock-q3-2026-earnings-skyrizi-rinvoq/article.md)
- [PDF](https://www.quantitativesuperintelligencelabs.com/research/abbvie-stock-q3-2026-earnings-skyrizi-rinvoq/abbvie-stock-q3-2026-earnings-skyrizi-rinvoq.pdf)
- [This agent brief](https://www.quantitativesuperintelligencelabs.com/research/abbvie-stock-q3-2026-earnings-skyrizi-rinvoq/llms.txt)

Publisher: QSI Labs (Quantitative Super Intelligence Labs)
Site index: https://www.quantitativesuperintelligencelabs.com/llms.txt